Skip to content
10-Q

Quarterly Report

PLIANT THERAPEUTICS, INC. PLRX

0001746473-26-000090

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 61.92M sh
Shares Diluted Q1 2026 · Mar 31, 2026 61.8M sh
Shares Diluted Q1 2026 · Mar 31, 2025 61.22M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $262K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$19.23M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$48.86M
Long Term Debt Q1 2026 · Mar 31, 2026 $0
Long Term Debt Q1 2026 · Dec 31, 2025 $0
Short Term Investments Q1 2026 · Mar 31, 2026 $148.7M
Short Term Investments Q1 2026 · Dec 31, 2025 $145.5M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $22.19M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $45.45M
Stockholders Equity Q1 2026 · Mar 31, 2026 $165.17M
Stockholders Equity Q1 2026 · Dec 31, 2025 $181.21M
Stockholders Equity Q1 2026 · Mar 31, 2025 $257.16M
Stockholders Equity Q1 2026 · Dec 31, 2024 $304.08M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.36M
Current Liabilities Q1 2026 · Dec 31, 2025 $16.37M
Total Liabilities Q1 2026 · Mar 31, 2026 $37.43M
Total Liabilities Q1 2026 · Dec 31, 2025 $44.02M
Current Assets Q1 2026 · Mar 31, 2026 $174.93M
Current Assets Q1 2026 · Dec 31, 2025 $196.45M
Total Assets Q1 2026 · Mar 31, 2026 $202.6M
Total Assets Q1 2026 · Dec 31, 2025 $225.23M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.32
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.92
Eps Basic Q1 2026 · Mar 31, 2026 −$0.32
Eps Basic Q1 2026 · Mar 31, 2025 −$0.92
Sga Expense Q1 2026 · Mar 31, 2026 $8.19M
Sga Expense Q1 2026 · Mar 31, 2025 $15.5M
Rd Expense Q1 2026 · Mar 31, 2026 $13.58M
Rd Expense Q1 2026 · Mar 31, 2025 $43.44M
Net Income Q1 2026 · Mar 31, 2026 −$20.04M
Net Income Q1 2026 · Mar 31, 2025 −$56.17M
Operating Income Q1 2026 · Mar 31, 2026 −$21.77M
Operating Income Q1 2026 · Mar 31, 2025 −$58.94M